

- 25 Chan DC, Watts GF, Ng TW, Uchida Y, Sakai N, Yamashita S *et al.* Adiponectin and other adipocytokines as predictors of markers of triglyceride-rich lipoprotein metabolism. *Clin Chem* 2005;51:578–85.
- 26 Chan DC, Watts GF, Ng TW, Yamashita S, Barrett PH. Effect of weight loss on markers of triglyceride-rich lipoprotein metabolism in the metabolic syndrome. *Eur J Clin Invest* 2008;38:743–51.
- 27 Ishigami M, Yamashita S, Sakai N, Hirano K, Hiraoka H, Nakamura T *et al.* Atorvastatin markedly improves type III hyperlipoproteinemia in association with reduction of both exogenous and endogenous apolipoprotein B-containing lipoproteins. *Atherosclerosis* 2003;168:359–66.
- 28 Westphal S, Wiens L, Güttler K, Dierkes J, Luley C. Chylomicron remnants of various sizes are lowered more effectively by fenofibrate than by atorvastatin in patients with combined hyperlipidemia. *Atherosclerosis* 2003;171:369–77.
- 29 Masuda D, Nakagawa-Toyama Y, Nakatani K, Inagaki M, Tsubakio-Yamamoto K, Sandoval JC *et al.* Ezetimibe improves postprandial hyperlipidaemia in patients with type IIb hyperlipidaemia. *Euro J Clin Invest* 2009;39:689–98.
- 30 Sandoval JC, Nakagawa-Toyama Y, Masuda D, Tochino Y, Nakaoka H, Kawase R *et al.* Molecular mechanisms of ezetimibe-induced attenuation of postprandial hypertriglyceridemia. *J Atheroscler Thromb* 2010;17:914–24.

